Otsuka Holdings Co., Ltd.: Depressive Disorder, Major trials

The registry lists 44 Depressive Disorder, Major studies with Otsuka Holdings Co., Ltd. as lead sponsor. 0 are open to participants now and 29 have results posted.

Phase 1 2Phase 2 8Phase 3 24Phase 4 4No phase 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Trial to Assess a Wearable Patch's Functioning to Detect Medication IngestionCompletedNCT06372210Not applicableResults posted
• Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive DisorderCompletedNCT04830215Phase 4Results posted
• Trial to Evaluate the Effectiveness of a Digital Therapeutics in Adults Diagnosed With Major Depressive DisorderCompletedNCT04770285Not applicableResults posted
• A Phase 2 Trial of OPC-64005 for Major Depressive DisorderCompletedNCT04244253Phase 2Results posted
• A Long-Term Study of Brexpiprazole in Patients With Major Depressive DisorderCompletedNCT03737474Phase 3Results posted
• A Study of Brexpiprazole in Patients With Major Depressive DisorderCompletedNCT03697603Phase 2/3Results posted
• A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive DisorderTerminatedNCT03643159Phase 4Results posted
• A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive DisorderCompletedNCT03538691Phase 3Results posted
• Exploratory Trial to Assess the Functionality of an Integrated Call Center for the Digital Medicine SystemCompletedNCT02722967Phase 2Results posted
• Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious DistressCompletedNCT02196506Phase 3Results posted
• Assess the Efficacy and Safety of ASC-01 in Patients With Major Depressive DisorderCompletedNCT02046564Phase 3Results posted
• Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work EnvironmentCompletedNCT02013609Phase 3Results posted
• Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety SymptomsCompletedNCT02013531Phase 3Results posted
• Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive TherapyCompletedNCT02012218Phase 3Results posted
• A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus TrialCompletedNCT01727726Phase 3Results posted
• Phase 1 Study to Assess the Safety/Tolerability of Brexpiprazole as Adjunctive Therapy in Elderly Subjects With Major Depressive DisorderCompletedNCT01670279Phase 1Results posted
• Study of Safety & Tolerability of OPC-34712 as Adjunctive Therapy in Treatment of Adult Patients With Major Depressive DisorderCompletedNCT01447576Phase 2Results posted
• Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)CompletedNCT01360866Phase 3Results posted
• Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)CompletedNCT01360645Phase 3Results posted
• Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)CompletedNCT01360632Phase 3Results posted
• To Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)TerminatedNCT01123707Phase 3Results posted
• Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)TerminatedNCT01111565Phase 3Results posted
• Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)TerminatedNCT01111552Phase 3Results posted
• Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)TerminatedNCT01111539Phase 3Results posted
• Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive DisorderCompletedNCT01052077Phase 2Results posted
• Long-Term Administration Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive DisorderCompletedNCT00882362Phase 3Results posted
• Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive DisorderCompletedNCT00876343Phase 3Results posted
• Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive DisorderCompletedNCT00797966Phase 2Results posted
• A Study of Aripiprazole in Patients With Major Depressive DisorderCompletedNCT00105196Phase 3Results posted
• A Study of SEP-380135 in Adults With Schizophrenia or Major Depressive EpisodeCompletedNCT07549581Phase 1
• A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive DisorderCompletedNCT05593029Phase 2
• Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive DisorderCompletedNCT05536414Phase 2
• Open-label Brexpiprazole fMRI Trial in Adults With Major Depressive Disorder and AnxietyWithdrawnNCT05504486Phase 4
• "Brexpiprazole (Rexulti™) Safety and Efficacy Among Filipino Patients (RAISE) - A Post Marketing Surveillance Program"Status unknownNCT04641780
• The Safety and Efficacy of Brexpiprazole as Adjunctive Therapy in the Treatment of Major Depressive DisorderTerminatedNCT03487198Phase 3
• Brexpiprazole (OPC 34712) Trial in the Treatment of Adults With Major Depressive Disorder and IrritabilityWithdrawnNCT02212613Phase 3
• Aripiprazole for the Augmentation of Antidepressant TherapyCompletedNCT01429831Phase 4
• Retrospective Database Study of Real World Abilify Outcomes in Major Depressive Disorder (MDD)CompletedNCT01284218
• Impact of Atypical Antipsychotic Therapy on Health Outcomes and Costs Among Patients With Major Depressive DisorderCompletedNCT01145313
• The Effect of Patient Cost-Sharing on Antidepressant and Adjunctive Therapy UseCompletedNCT01141400
• Outcomes in MEasurement-Based TreatmentCompletedNCT01141387
• A Study of Adjunctive Aripiprazole in Patients With Major Depressive DisorderCompletedNCT00095823Phase 3
• A Study of Adjunctive Aripiprazole in Participants With Major Depressive DisorderCompletedNCT00095758Phase 3
• A Long-Term Study of Aripiprazole in Patients With Major Depressive DisorderCompletedNCT00095745Phase 3